> Chemicals & Drugs > Organic Chemical > Fibrates

Ficoll →

Fibrates

Most cited protocols related to «Fibrates»

Extracting Lipid and Diabetes Traits from EMRs

Cited 8 times

EMRs contain structured [International Classification of Diseases or ICD-9 (billing) codes and Current Procedural Terminology or CPT (procedure) codes; clinical lab test results, semi-structured, and unstructured (clinical notes) data, all of which can be used for electronic phenotyping. The data types currently available in the SD that can be accessed for electronic phenotyping include narratives (such as clinical notes, discharge summaries, history and physicals, problem lists, surgical reports, progress notes, letters), ICD-9 codes, CPT codes, forms (intake, assessment), reports [pathology, electrocardiograms (ECGs), echocardiograms], clinical communications, lab values and vital signs, medication orders, TraceMaster (ECGs), and the tumor registry [41 (link)].
Electronic phenotyping has been previously described for BMI in EAGLE BioVU [42 ]. To extract lipid and type 2 diabetes traits from EAGLE BioVU EMRs, laboratory measurements were queried for glucose, HbA1c, HDL-C, insulin, LDL-C, total cholesterol, and triglycerides. Records were also queried for calculated LDL-C. Prescription medication is available in the SD through MedEx [43 (link)], an algorithm that extracts medications and their signature mentions from free-text entries available in the EMR.
For each adult patient (>18 years), median values were calculated for a) measurements taken when no medications are prescribed (“pre-medication” values) and b) measurements taken at first mention of medication and post mention of medication (“post-medication” values). We used the following medication class and list to identify lipid measurements determined at the time or after patients were prescribed lipid-lowering medications

Statins (also known as HMG CoA reductase inhibitors, atorvastatin (Lipitor®), fluvastatin (Lescol®), lovastatin (Mevacor®, Altoprev™), pravastatin (Pravachol®), rosuvastatin calcium (Crestor®), simvastatin (Zocor®), lovastatin + niacin (Advicor®), atorvastatin + amlodipine (Caduet®), and simvastatin + ezetimibe (Vytorin™)

Selective cholesterol absorption inhibitors (ezetimibe (Zetia®))

Resins (cholestyramine (Questran®, Questran® Light, Prevalite®, Locholest®, Locholest® Light), colestipol (Colestid®), colesevelam Hcl (WelChol®))

Fibrates (gemfibrozil (Lopid®), fenofibrate (Antara®, Lofibra®, Tricor®, and Triglide™), clofibrate (Atromid-S))

Niacin

Crawford D.C., Goodloe R., Farber-Eger E., Boston J., Pendergrass S.A., Haines J.L., Ritchie M.D, & Bush W.S. (2015). Leveraging epidemiologic and clinical collections for genomic studies of complex traits. Human heredity, 79(0), 137-146.

Publication 2015

Adult Advicor Amlodipine Anticholesteremic Agents Atorvastatin Atromid Caduet Cholesterol Clofibrate Colesevelam Hydrochloride Colestipol Crestor Diabetes Mellitus, Non-Insulin-Dependent Eagle Echocardiography Electrocardiogram Ezetimibe Fenofibrate Fibrates Fluvastatin Gemfibrozil Glucose Hydroxymethylglutaryl-CoA Reductase Inhibitors Insulin Lescol Light Lipids Lipitor Lofibra Lopid Lovastatin lovastatin-niacin combination Mevacor Neoplasms Niacin Operative Surgical Procedures Patient Discharge Patients Pharmaceutical Preparations Physical Examination Pravachol Pravastatin Questran Resin, Cholestyramine Resins, Plant Rosuvastatin Calcium Signs, Vital Simvastatin Tricor Triglycerides Vytorin Welchol Zetia Zocor

Fibrate Therapy and Stroke Risk

Cited 7 times

Randomized, double-blind, placebo-controlled, and trials of fibrate therapy in English-language literature were eligible for inclusion in our research, regardless of publication status (published, unpublished, in press, or in progress). References of our meta-analysis were identified through searches of Pubmed, EmBase, and the Cochrane Central Register of Controlled Trials, with a date up to Dec 10, 2011. We searched with the following terms “clofibrate”, “bezafibrate”, “gemfibrozil”, “fenofibrate”, “procetofen”, and “randomised controlled trials”. The search was restricted to trials in human beings and published in English. References were also identified by screening the proceedings of annual meeting, bibliographies of publications for potentially relevant trials. We restricted our research to randomized controlled trials, which were less likely to be subject to confounding and bias than observational studies. Studies were eligible for inclusion when they met the following requirements: randomized controlled design; the intervention duration was at least 6 months and follow-up period was more than 12 months; recorded data on the event of stroke. The literature search was undertaken independently by 2 authors (Fei-Fei Yu and Ying-Yi. Qin) with a standardized approach, and any disagreement between these 2 authors was settled by a third author (Yu-Hao. Zhou) until a consensus was reached. This review was conducted and reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) Statement issued in 2009 (Additional file 1) [11 ].

Zhou Y.H., Ye X.F., Yu F.F., Zhang X., Qin Y.Y., Lu J, & He J. (2013). Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention. BMC Neurology, 13, 1.

Full text: Click here

Publication 2013

Bezafibrate Cerebrovascular Accident Clofibrate Fenofibrate Fibrates Gemfibrozil Homo sapiens Placebos prisma Therapeutics

Lipid Profiles and Genetic Associations

Cited 6 times

The participants were recruited from Dongxing City, Guangxi Zhuang Autonomous Region, People's Republic of China in 2012. A total of 1869 participants were randomly selected from our stratified, randomized samples 41. There were 999 hyperlipidaemic (TC > 5.17 mmol/l and/or TG > 1.70 mmol/l) and 870 normolipidaemic (TC ≤ 5.17 mmol/l and TG ≤ 1.70) individuals, aged 18–80 years. The age and gender distribution were matched between the two populations. The participants with a history of CVD including coronary artery disease and stroke, diabetes, chronic illness including cardiac, renal, thyroid problems and/or a history of taking lipid‐modulating medications such as statins or fibrates were excluded. Within the hyperlipidaemic population to assess the association of SNPs with risk of HCH and HTG separately, the hyperlipidaemic populations were subdivided into hypercholesterolaemic (TC > 5.17 mmol/l) and hypertriglyceridaemic (TG >1.70 mmol/l) groups. Informed consents were obtained from all the participants after they have received a full explanation of the study. The study was reviewed and approved by the Ethics Committee of the First Affiliated Hospital, Guangxi Medical University.

Guo T., Yin R., Lin W., Wang W., Huang F, & Pan S. (2015). Association of the variants and haplotypes in the DOCK7, PCSK9 and GALNT2 genes and the risk of hyperlipidaemia. Journal of Cellular and Molecular Medicine, 20(2), 243-265.

Full text: Click here

Publication 2015

Cerebrovascular Accident Coronary Arteriosclerosis Diabetes Mellitus Disease, Chronic Ethics Committees, Clinical Fibrates Gender Heart Hydroxymethylglutaryl-CoA Reductase Inhibitors Kidney Lipid A Pharmaceutical Preparations Single Nucleotide Polymorphism Thyroid Gland

Metabolic Syndrome Measures in Vietnam Era Twin Study

Cited 6 times

This study is based on 1193 participants (330 monozygotic [MZ] pairs, 233 dizygotic [DZ] pairs, 67 unpaired twins) from wave 2 of the Vietnam Era Twin Study of Aging (VETSA)^{15 (link)}. VETSA is a longitudinal study of midlife risk and protective influences on cognitive aging in a community-dwelling sample^{16 (link)}. At baseline, 1237 individual twins were randomly recruited from twin pairs in the nationally representative Vietnam Era Twin Registry, an all-male registry^{17 (link)}. At wave 2, twins were on average 61.7 years old (SD 2.4; range 56-66.9). The sample is predominantly of European descent. Although participants were all veterans, nearly 80% reported no combat exposure. Health and lifestyle characteristics are comparable to American men in this age group¹⁸.
Zygosity was primarily determined by 25 microsatellite markers; for 8% of the sample zygosity was determined by questionnaires and blood group, with 95% agreement with DNA-based results. Participants underwent medical history interviews which elicited information about prescription medications. Written informed consent was obtained from all participants. Metabolic syndrome measures.
After removing shoes and heavy outer clothing, participants were weighed to the nearest half pound on a digital scale and height was assessed with a stadiometer. Body mass index (BMI) was calculated as: Weight (kg)/Height² (m²). Waist circumference was measured as the smallest horizontal circumference between the 12^th rib and the iliac crest.
Morning and afternoon systolic and diastolic BP (SBP, DBP) measurements were obtained in a seated position using automated sphygmomanometers. After waiting quietly for five minutes, BP was measured twice with one-minute breaks between readings. SBP and DBP scores were averages of the four readings. Triglycerides and HDL (mmol/L), insulin (pmol/L), and glucose (mmol/L) were assayed from fasting blood samples at certified laboratories (Nichols Institute/Quest Diagnostics, San Juan Capistrano, CA).
Medications were categorized and organized by RLH, KK*, MS, and CEF according to mechanism of action and indication. Medication adjustments for BP were based on previous work showing that taking into account drug class, number of antihypertensive drugs, and ethnicity was optimal; depending on these characteristics, values added to SBP/DBP measures ranged from 14-38/9-27mmHg, respectively^{19 (link)}. Based on Wu et al,^{20 (link)}, HDL and triglycerides were adjusted by drug class, ethnicity, and number of statin or fibrate drugs taken.
To account for skewness and effects of diabetes-related medications, ordinal measures were created for insulin and glucose to approximate normal distributions. Glucose was divided into 10 categories. The first seven represented glucose levels in individuals not taking diabetes-related medications; the last three represented individuals who were taking medication. Insulin level was divided into five categories. The first four represented individuals not taking diabetes-related medication. Many individuals had the lowest detectable value; thus, more insulin categories could not be created. All diabetes was type 2 as those with type 1 diabetes were not inducted into the military.

Panizzon M., Hauger R.L., Sailors M., Lyons M.J., Jacobson K.C., Murray R.E., Rana B., Vasilopoulos T., Vuoksimaa E., Xian H., Kremen W.S, & Franz C.E. (2015). A New Look at the Genetic and Environmental Coherence of Metabolic Syndrome Components. Obesity (Silver Spring, Md.), 23(12), 2499-2507.

Publication 2015

Antihypertensive Agents BLOOD Diabetes Mellitus Diabetes Mellitus, Insulin-Dependent Diagnosis Drug Kinetics Ethnicity Europeans Fibrates Glucose Hydroxymethylglutaryl-CoA Reductase Inhibitors Iliac Crest Index, Body Mass Insulin Males Metabolic Syndrome X Military Personnel Pharmaceutical Preparations Prescription Drugs Pressure, Diastolic Short Tandem Repeat Sitting Sphygmomanometers Systole Triglycerides Twins Veterans Waist Circumference

Comprehensive Safety Monitoring in Clinical Trial

Cited 6 times

Study follow-up visits were conducted at 3 and 6 months following randomization and then 6 monthly. Study clinic staff systematically sought information on all serious adverse events, any non-serious adverse events considered by participants to be related to, or that resulted in stopping, study treatment, on muscle pain or weakness, and on symptoms suggestive of hepatitis (nausea, vomiting, or jaundice). The coordinating centre sought further details from the participant's medical records about all reports that might relate to MVEs or safety outcomes, and from national registries (where available) about cancers and the certified causes of any deaths. All such information was reviewed by coordinating centre clinicians (blind to treatment allocation) and events adjudicated according to pre-specified criteria.
Compliance with study treatment was assessed and, if relevant, a reason for discontinuation was recorded. Participants prescribed contra-indicated drugs (non-study niacin or fibrates) had their randomized treatment (ERN/LRPT or placebo) stopped. Those who were prescribed a non-study statin or drugs known to increase the risk of statin-induced myopathy had their study LDL-lowering treatment stopped. At each follow-up visit, dry chemistry analysers were used to measure ALT and, if ALT >1.5× ULN or muscle symptoms were reported, also CK. Externally measured CK and ALT results associated with events of interest were also recorded in the study database and included in these analyses. Consecutive elevations of ALT >3× ULN, any ALT >10× ULN or ALT >3× ULN with bilirubin ≥2× ULN without clear alternative causes led to permanent discontinuation of randomized treatment. Persistent CK >10× ULN without muscle symptoms or >5× ULN with muscle symptoms led to discontinuation of both study treatments. Other elevations of ALT or CK were managed (including recall visits to reassess symptoms and measure ALT and CK levels) after review by coordinating centre clinicians in collaboration with doctors at the local site, with the aim of minimizing myopathy or liver injury risk.

Haynes R., Jiang L., Hopewell J.C., Li J., Chen F., Parish S., Landray M.J., Collins R., Armitage J., Collins R., Armitage J., Baigent C., Chen Z., Landray M., Chen Y., Jiang L., Pedersen T., Landray M., Bowman L., Chen F., Hill M., Haynes R., Knott C., Rahimi K., Tobert J., Sleight P., Simpson D., Parish S., Baxter A., Lay M., Bray C., Wincott E., Leijenhorst G., Skattebol A., Moen G., Mitchel Y., Kuznetsova O., MacMahon S., Kjekshus J., Hill C., Lam T.H., Sandercock P., Peto R, & Hopewell J.C. (2013). HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal, 34(17), 1279-1291.

Publication 2013

Asthenia Bilirubin Blindness Fibrates Hepatitis Hydroxymethylglutaryl-CoA Reductase Inhibitors Icterus Injuries Liver Malignant Neoplasms Mental Recall Muscle Tissue Myalgia Myopathy Nausea Niacin Pharmaceutical Preparations Physicians Placebos Safety

Most recents protocols related to «Fibrates»

Myocardial Fat Accumulation in Type 2 Diabetes

We searched the database of patients with type 2 diabetes who were referred for ECG-gated coronary computed tomography angiography (CCTA) examinations (Toshiba Aquilion CT scanner, Toshiba Medical, Tochigi, Japan; SOMATOM Definition or Force, Siemens Healthineers, Forchheim, Germany) for the first time and underwent abdominal CT scans (Toshiba Aquilion CT scanner, Toshiba Medical, Tochigi, Japan; Discovery CT750 HD, General Electric Healthcare, Chicago, IL, USA; SOMATOM Definition, Siemens Healthineers, Forchheim, Germany; GE Optima CT660, General Electric Healthcare, Chicago, IL, USA) within 1 year of CCTA at Osaka University Hospital or Sumitomo Hospital between January 2000 and March 2021. A total of 411 patients met these criteria. Among these patients, we excluded patients to avoid the influence of cardiac function or the myocardial CT value of pathological conditions other than myocardial fat accumulation. The excluded patients included those with heart failure with reduced ejection fraction (≤ 40%), those with valvular heart disease and those who had received past percutaneous coronary intervention (PCI) for coronary artery disease. Moreover, we excluded patients who had liver cirrhosis, renal failure (estimated glomerular filtration rate of < 30 mL/min/1.73 m²), malignant diseases and diseases requiring glucocorticoids for the treatment of other diseases. Furthermore, it is known that changes in X-ray tube voltage affect CT attenuation values [20 (link)]. Therefore, patients who underwent CCTA or abdominal CT examinations that were not performed at 120 kV were excluded. Using these criteria, 124 patients were finally included in our analyses. The flowchart for the recruitment of the patients is shown in Additional file 1: Fig S1. Among these 124 patients, the medications for diabetes at the time of CCTA were as follows: insulin for 42 patients, glucagon-like peptide-1 (GLP-1) receptor agonists for 9 patients, sulfonylureas for 31 patients, biguanides for 43 patients, dipeptidyl peptidase-4 inhibitors for 40 patients, α-glucosidase inhibitors for 26 patients, thiazolidinediones for 13 patients, glinides for 12 patients and sodium–glucose cotransporter 2 (SGLT2) inhibitors for 3 patients. The medications for dyslipidemia at the time of CCTA were as follows: statins for 69 patients, fibrates for 9 patients, ezetimibe for 5 patients, omega-3 fatty acids for 8 patients and probucol for 1 patient.
This study was approved by the Institutional Ethics Review Boards of Osaka University Hospital and Sumitomo Hospital and was carried out in accordance with the principles of the Declaration of Helsinki. The study was announced to the public on the websites of our department at Osaka University Hospital and Sumitomo Hospital, and all patients were allowed to participate or refuse to participate in the study.

Kashiwagi-Takayama R., Kozawa J., Hosokawa Y., Kato S., Kawata S., Ozawa H., Mineo R., Ishibashi C., Baden M.Y., Iwamoto R., Saisho K., Fujita Y., Tamba S., Sugiyama T., Nishizawa H., Maeda N., Yamamoto K., Higashi M., Yamada Y., Sakata Y., Matsuzawa Y, & Shimomura I. (2023). Myocardial fat accumulation is associated with cardiac dysfunction in patients with type 2 diabetes, especially in elderly or female patients: a retrospective observational study. Cardiovascular Diabetology, 22, 48.

Full text: Click here

Publication 2023

Abdomen agonists alpha-Glucosidase Inhibitors Biguanides Cardiomyopathies CAT SCANNERS X RAY Computed Tomography Angiography Congestive Heart Failure Coronary Artery Disease Diabetes Mellitus Diabetes Mellitus, Non-Insulin-Dependent Dipeptidyl-Peptidase IV Inhibitors Dyslipidemias Electricity Ezetimibe Fibrates Glomerular Filtration Rate Glucagon-Like Peptide-1 Receptor Glucocorticoids Heart Hydroxymethylglutaryl-CoA Reductase Inhibitors inhibitors Insulin Kidney Failure Liver Cirrhosis Myocardium Omega-3 Fatty Acids Patients Pharmaceutical Preparations Physical Examination Probucol Radiography SLC5A2 protein, human Sulfonylurea Compounds Thiazolidinediones Valve Disease, Heart X-Ray Computed Tomography

Vitamin D Analog for Uterine Prolapse

This was a quasi-experimental study with a pre-post design that analyzes the effect of Vitamin D analog supplementation in women with uterine prolapse. We included all postmenopausal women diagnosed with grade III and IV uterine prolapse who came to outpatient clinic of Dr. Hasan Sadikin Bandung from August 2021 to November 2021. Uterine prolapse diagnosis and staging were based on Pelvic Organ Prolapse Quantification (POP-Q) system. Exclusion criteria were as follows:

Patients with comorbidities, such as chronic cough and chronic constipation (these symptoms last for a minimum of 8 weeks).

Patients diagnosed with diseases related to Vitamin D metabolism disorders such as: diabetes mellitus, chronic kidney failure, or malignant diseases

Those who had a history of gastrectomy or jejunoileostomy surgery.

Patients who are currently or have a history of taking cholesterol-lowering drugs (statins and fibrates), anticonvulsants, thiazides, theophylline, orlistat, cimetidine, and Vitamin D supplementation one month prior to this study.

Patients withdrawing from our research.

During the initial presentation, we collected the following data: age, parity, body mass index (BMI), hemoglobin levels, and calcium levels. All subjects were then given 0.5 mcg of Vitamin D analog supplementation for 3 months. We also collected and compared the following data before and after Vitamin D analog supplementation: (1) Vitamin D and VDR serum levels, (2) Levator ani muscle strength, and (3) Hand grip muscle strength. Levator ani muscle strength was measured using perineometer, while handgrip muscle strength was evaluated using hand grip dynamometer.
We tabulated all patients' data on a customized spreadsheet and performed data analysis on Statistical Produce and Service Solutions SPSS software version 25 for Windows (IBM Corp, Armonk, New York, USA). Descriptive statistics were performed as appropriate. Analytical statistics were performed using t test or Wilcoxon test as required, with p < 0.05 considered as significant.
Written informed consent was provided to all study participants prior to engaging in any study-related procedures. Ethical approval of this study was granted by the Health Research Ethics Committee of Hasan Sadikin Hospital, Bandung under the following registration number: LB.02.01/X.6.5/213/2021. This study was conducted according to Declaration of Helsinki. All research procedures were performed in accordance with relevant guidelines and regulations.

Kurniadi A., Dewi A.K., Sasotya R.M., Purwara B.H, & Kireina J. (2023). Effect of Vitamin D analog supplementation on levator ani strength and plasma Vitamin D receptor expression in uterine prolapse patients. Scientific Reports, 13, 3616.

Full text: Click here

Publication 2023

Anticholesteremic Agents Anticonvulsants Calcium, Dietary Cimetidine Constipation Cough Diabetes Mellitus Ergocalciferol Ethics Committees, Clinical Fibrates Gastrectomy Grasp Hemoglobin Hydroxymethylglutaryl-CoA Reductase Inhibitors Index, Body Mass Kidney Failure, Chronic Metabolic Diseases Muscle Strength Muscle Tissue Operative Surgical Procedures Orlistat Patients Pelvic Organ Prolapse Serum Theophylline Thiazides Uterine Prolapse Woman

Cardiometabolic Outcomes in Italian-Born and HMPC Residents

First, the demographic and lifestyle characteristics of HMPC-born residents and natives were compared.
Participants who had reported using cholesterol-lowering medications such as statins, fibrates and red rice were excluded for serum lipid outcomes (n = 1,676), and participants with a self-reported diagnosis of hypertension or under treatment with antihypertensive medications were excluded for continuous blood pressure outcomes (n = 4,859), leaving 35,704 and 32,521 subjects included for the lipid and blood pressure analyses, respectively (Supplementary Figure S1).
We used generalized linear regression models (LMs) to investigate the differences between cardiometabolic outcomes (SBP, DBP, TC and LDL-C) among HMPCs and the specific macro-areas of birth compared to native-born Italians. Basic models were adjusted only for age (continuous) and sex, while fully adjusted models were additionally adjusted for the whole set of covariates. For TC and LDL-C, a random intercept was added to the models, running linear regression mixed models (LMMs) to account for the laboratory in charge of the serum analyses. For the analyses of the association of migratory status with hypertension prevalence, a log link function was used in the models, and prevalence ratios (PRs) were calculated. Estimates and 95% confidence intervals (95% CI) were reported.
Each HMPC category based on age at arrival and length of stay in Italy was then compared to native-born Italians, using the same previously defined models for each outcome. This analysis was also conducted for each of the three macro-areas with sufficient sample sizes (CE Europe, Northern Africa, Asia).
All analyses were stratified by sex.
Analyses were performed using the statistical software Stata/SE version 13.0 (Stata Corp LP, College Station, TX, USA) and R (R Development Core Team 2010, R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL: http://www.R-project.org/). We employed the “lme4” and “prLogistic” packages to run LMMs and calculate prevalence ratios, respectively.

Dalla Zuanna T., Batzella E., Pitter G., Russo F., Spadea T, & Canova C. (2023). Adult first-generation immigrants and cardiovascular risk factors in the Veneto Region, Northeast Italy. Frontiers in Public Health, 11, 956146.

Full text: Click here

Publication 2023

Anticholesteremic Agents Antihypertensive Agents Birth Blood Pressure Childbirth Diagnosis Fibrates Hematologic Tests High Blood Pressures Hydroxymethylglutaryl-CoA Reductase Inhibitors Lipids Natives Oryza sativa Pharmacotherapy Pressure Serum

Pharmaceutical Metabolites Profiling in Aquatic Environment

A total of 11 pharmaceutical metabolites and 11 of their parents were selected as target pharmaceuticals in this study based on the occurrence of pharmaceuticals in the aquatic environment of the lower reach of the Yangtze River Delta Region [14 (link),16 (link)], including sulfonamide antibiotics, nonsteroid anti-inflammatory drug, fibrate drug, and psychoactive drug. Given that a pharmaceutical has more than one metabolite, the bioactive one detected most frequently in water was used in this study. The basic physical and chemical properties of these pharmaceuticals are listed in Table 1. All of these pharmaceuticals were obtained from Dr. Ehrenstorfer (Augsburg, Germany) or J&K Chemical Ltd. (Shanghai, China) with a high purity grade (>98%). All solvents used in the study were purchased from Merck (Darmstadt, Germany) with a high-performance liquid chromatography (HPLC) grade.

Yan Z., Zhou Y., Zhang Y, & Zhang X. (2023). Distribution, Bioaccumulation, and Risks of Pharmaceutical Metabolites and Their Parents: A Case Study in an Yunliang River, Nanjing City. International Journal of Environmental Research and Public Health, 20(4), 2967.

Full text: Click here

Publication 2023

Anti-Inflammatory Agents, Non-Steroidal Antibiotics, Antitubercular chemical properties Fibrates High-Performance Liquid Chromatographies Parent Pharmaceutical Preparations Physical Examination Psychotropic Drugs Rivers Solvents Sulfonamides

Cardiovascular Risk Profile of HIV Patients

This is a cross-sectional study comprising of 265 consecutive patients who attended the HIV/AIDS outpatient clinic, in previously scheduled appointments, at the Professor Edgard Santos University Hospital (HUPES) of the Federal University of Bahia (UFBA), between October 2020 and October 2021. The study is part of the Brazilian HIV-AIDS cohort (CoBRA), approved by the Research Ethics Committee of the Faculty of Medicine of Bahia (opinion number 1,035,826) and in accordance with the Declaration of Helsinki.
Socio-demographic variables were collected (age in years, sex, skin color and city of origin) and the participant’s medical history was reviewed to identify the occurrence of previous CVD (AMI, ischemic or hemorrhagic stroke, CHF, peripheral arterial disease and angina pectoris), diabetes mellitus (DM) (previous diagnosis and/or treatment), AH (previous diagnosis and/or medication use), use of lipid-lowering drugs (fibrate and/or statin), family history of early coronary artery disease (HECAD) (AMI or sudden death before age 55 in a male father or other first-degree relative, or before age 65 in a female mother or other first-degree relative); chronic kidney disease (previous diagnosis), smoking (current use, past use, if stopped for more than two last years, or never) and weekly alcohol use. Information on the time of diagnosis of HIV infection and the time of exposure to ART (in years), in addition to the mode of acquisition of HIV (heterosexual sexual relations, men who have sex with men (MSM) and others/not defined), were also recorded.
During the evaluation, weight (kg) and height (meters) were measured using an anthropometric scale. Systolic blood pressure (SBP) and diastolic blood pressure (DBP), in mmHg, were measured in the upper limbs (after five minutes of rest, in the supine position, with a digital sphygmomanometer). Body mass index (BMI) considered overweight and obesity as BMI ≥ 25 kg/m² and >30 kg/m², respectively. Abdominal circumference (AC) measurements were taken, considered to be increased if >102 cm in men and >88 cm in women. Lipid profile was considered altered if total cholesterol (TC) > 190 mg/dL, HDL < 40 mg/dL, LDL >130 mg/dL and triglycerides (TG) >150 mg/dL. The last CD4 cell count (cells/mL), the most recent HIV-RNA plasma viral load (values below 40 copies/mL were considered undetectable), in addition to fasting glucose (mg/dL) and serum creatinine (mg/dL) were recorded.

Souza V., Valadares V., Dias T, & Brites C. (2023). High Concordance between D:A:Dr and the Framingham Risk Score in Brazilians Living with HIV. Viruses, 15(2), 348.

Full text: Click here

Publication 2023

Abdomen Acquired Immunodeficiency Syndrome Angina Pectoris Birth CD4+ Cell Counts Cells Cholesterol Chronic Kidney Diseases Cobra Coronary Arteriosclerosis Creatinine Diabetes Mellitus Diagnosis Ethics Committees, Research Faculty Fibrates Glucose Hemorrhagic Stroke Heterosexuals HIV Infection Diagnosis Hydroxymethylglutaryl-CoA Reductase Inhibitors Index, Body Mass Lipids Males Mothers Obesity Patients Peripheral Vascular Diseases Pharmaceutical Preparations Plasma Pressure, Diastolic Serum Skin Pigmentation Sphygmomanometers Sudden Death Systolic Pressure Triglycerides Upper Extremity Woman

Top products related to «Fibrates»

Integra 400 analyzer by Roche

Sourced in Germany

The Roche/Integra 400 Analyzer is a compact, automated clinical chemistry analyzer designed for in-vitro diagnostic testing. It is capable of performing a wide range of routine and specialty chemistry tests on a variety of sample types, including serum, plasma, and urine. The analyzer utilizes proven photometric technology to deliver accurate and reliable results.

Cobas integra 400 by Roche

Sourced in Switzerland, Germany, United States, Australia, Canada, United Kingdom, Spain

The Cobas Integra 400 is a versatile, automated clinical chemistry analyzer designed for use in medical laboratories. It is capable of performing a wide range of clinical chemistry tests, including assays for enzymes, substrates, and electrolytes. The Cobas Integra 400 is equipped with advanced technology to ensure accurate and reliable results, and it is designed to streamline laboratory workflow and improve efficiency.

Wy14643 by Merck Group

Sourced in United States, China, Germany, United Kingdom

WY14643 is a laboratory chemical product manufactured by Merck Group. It is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. The core function of WY14643 is to serve as a research tool for studies related to PPARα activation and its effects in various biological systems.

Fenofibrate by Merck Group

Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, Macao, Japan, China, France

Fenofibrate is a laboratory equipment product manufactured by Merck Group. It is a type of lipid-regulating agent used in pharmaceutical research and development. The core function of Fenofibrate is to help regulate and manage lipid levels in biological samples.

Spss 22nd edition by IBM

Sourced in United States

SPSS 22nd edition is a comprehensive statistical analysis software package developed by IBM. It provides a range of analytical tools for data management, exploration, modeling, and reporting. SPSS 22nd edition is designed to help users analyze and interpret complex data from various sources, including surveys, experiments, and observational studies.

Matlab software by MathWorks

Sourced in United States, United Kingdom, Germany, Morocco, Sweden

MATLAB is a high-performance numerical computing software that provides a powerful programming environment for technical and scientific computing. It is designed to perform matrix and array operations, data analysis, and visualization tasks. MATLAB offers a wide range of built-in functions and toolboxes for various applications, such as signal processing, control systems, and image processing.

Liraglutide by Novo Nordisk

Sourced in Denmark, United States, China, United Kingdom, Japan

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is a synthetic version of the naturally occurring GLP-1 hormone, which plays a role in regulating blood glucose levels.

Modular p by Roche

Sourced in Germany, United States, Switzerland, United Kingdom

The Modular P is a versatile and automated laboratory instrument designed for clinical chemistry analysis. It features a modular design that allows for customization to meet the specific needs of a laboratory. The Modular P is capable of performing a wide range of clinical chemistry tests, including assays for enzymes, substrates, and electrolytes. The instrument is designed for high-throughput operation and can process a large number of samples efficiently.

Spss version 18 by IBM

Sourced in United States, United Kingdom, Japan, Thailand, China, Italy, Germany

SPSS version 18.0 is a statistical software package developed by IBM. It provides data management, analysis, and reporting capabilities. The core function of SPSS is to assist in the analysis of data and presentation of results.

Spss v20 by IBM

Sourced in United States, Germany, United Kingdom, Belgium, Japan, China, Austria, Denmark

SPSS v20 is a statistical software package developed by IBM. It provides data management, analysis, and visualization capabilities. The core function of SPSS v20 is to enable users to perform a variety of statistical analyses on data, including regression, correlation, and hypothesis testing.

What are fibrates and how do they work?

What are some common usage challenges with fibrates?

One common challenge with fibrates is the potential for drug interactions, particularly with statins. Fibrates can increase the risk of myopathy and rhabdomyolysis when used in combination with certain statins. Patients taking fibrates may also need to be monitored for potential side effects, such as gastrointestinal issues, liver function abnormalities, and increased risk of gallbladder disease. Adherence to dosage instructions and regular check-ups with a healthcare provider are important to manage these challenges.

How can PubCompare.ai help with fibrates research?

PubCompare.ai allows researchers to screen protocol literature more efficiently and leverage AI to pinpoint critical insights. The platform can help identify the most effective protocols related to fibrates for your specific research goals. PubCompare.ai's AI-driven analysis can highlight key differences in protocol effeciveness, enabling you to choose the best option for reproducibility and accuarcy.

Are there different types or variations of fibrates?

Yes, there are several different types of fibrates, each with their own unique properties and potential applications. The most common fibrates include fenofibrate, gemfibrozil, and bezafibrate. These drugs can vary in their potency, pharmacokinetics, and specific effects on lipid profiles. Researchers may need to consider the unique characteristics of each fibrate when designing studies or determining the most appropriate treatment approach for their research or clinical setting.

More about "Fibrates"

Fibrates are a class of lipid-lowering medications that can help reduce levels of triglycerides and increase high-density lipoprotein (HDL) cholesterol.
These drugs work by activating peroxisome proliferator-activated receptor alpha (PPAR-α), which regulates genes involved in lipid and carbohydrate metabolism.
Fibrates are commonly used to treat hypertriglyceridemia and to reduce the risk of cardiovascular events in patients with dyslipidemia.
Examples of fibrates include fenofibrate, gemfibrozil, and bezafibrate.
Researchers can optimize their fibrates research by utilizing PubCompare.ai, a leading AI-driven platform that can help locate relevant protocols from literature, preprints, and patents.
The platform's AI-driven comparisons can identify the most effective protocols and products, enhancing research reproducibility and accuracy.
Some key subtopics and related terms to consider include lipid metabolism, triglycerides, HDL cholesterol, PPAR-α agonists, hypertriglyceridemia, dyslipidemia, fenofibrate, gemfibrozil, bezafibrate, Roche/Integra 400 Analyzer, Cobas Integra 400, WY14643 (a PPAR-α agonist), SPSS (Statistical Package for the Social Sciences), MATLAB (a numerical computing environment), Liraglutide (a GLP-1 agonist), and Modular P (a laboratory automation system).
By incorporating these terms and leveraging the power of PubCompare.ai, researchers can optimize their fibrates research and drive meaningful insights.